Home / Business and Economy / CEO Buys Millions in Stock Indirectly
CEO Buys Millions in Stock Indirectly
7 Jun
Summary
- CEO Kevin Tang acquired over 814,000 shares indirectly via investment funds.
- Tang's indirect stake now totals over 13 million shares.
- Aurinia Pharma shares have surged 93.3% in the past year.
Kevin Tang, Chief Executive Officer of Aurinia Pharmaceuticals Inc., reported the purchase of 814,606 common shares between May 29 and June 2, 2026. These shares were acquired indirectly through investment funds managed by Tang, with the weighted average purchase price noted at $15.29 per share.
Following these transactions, Tang's indirect ownership in Aurinia Pharmaceuticals now stands at 13,044,106 shares. He also holds indirect exposure to an additional 10,000 shares via outstanding short put options. This recent acquisition aligns with Tang's historical trading patterns of periodic, substantial share purchases.
Aurinia Pharmaceuticals, a commercial-stage biotechnology company, focuses on developing therapies for autoimmune diseases. Its primary product is LUPKYNIS, an FDA-approved oral treatment for active lupus nephritis. The company's stock has performed exceptionally well, increasing by 93.3% over the preceding year as of June 2, 2026.
